This trial report describes the background and design for the Japan Intergroup Trial of Pemetrexed Adjuvant Chemotherapy for Completely Resected Nonsquamous NoneSmall-Cell Lung Cancer (JIPANG) study (University Hospital Medical Information Network database: UMIN000006737). Various randomized trials have shown the efficacy of postoperative adjuvant chemotherapy regimens that include cisplatin for resected nonesmall-cell lung cancer (NSCLC), but the optimal regimen is not known. The JIPANG study is a randomized study comparing cisplatin (75 mg/m 2 , day 1) and pemetrexed (500 mg/m 2 , day 1) with cisplatin (80 mg/m 2 , day 1) and vinorelbine (25 mg/m 2 , days 1 and 8) for nonsquamous NSCLC as postoperative adjuvant chemotherapy. A total of 804 patients with pathological stage II to IIIA completely resected nonsquamous NSCLC were enrolled in this study between March 2012 and August 2016. These patients have been randomized in a 1:1 ratio and stratified according to sex (female vs. male), age (< 70 years vs. 70 years), pathologic stage (II vs. IIIA), mutation of the epidermal growth factor receptor (mutant vs. wild) and institution. Each treatment will be undertaken every 3 weeks until 4 cycles have been completed. The primary endpoint is overall survival and the secondary endpoints are disease-free survival, rate of treatment completion, and incidence of adverse events. This design has 80% power to detect overall survival with a hazard ratio of 0.786 (a ¼ 1-sided 0.05) with 5-year follow-up after registration of the final patient. This study will show a superior regimen for completely resected nonsquamous NSCLC. Biomarker analyses of the JIPANG study are ongoing.
Introduction
The efficacy of postoperative adjuvant chemotherapy including cisplatin for nonesmall-cell lung cancer (NSCLC) was reported first in 2004. [1] [2] [3] A meta-analysis of 4584 patients enrolled in a large-scale comparative study of cisplatin-based postoperative chemotherapy (the Lung Adjuvant Cisplatin Evaluation [LACE] ) showed that the hazard ratio against death in all patients was 0.89 (95% confidence interval, 0.82-0.96), which corresponded to an absolute survival benefit of 5.4% at 5 years. 4 In addition, subgroup analyses of the LACE study showed that only vinorelbine significantly prolonged Registered in the University Hospital Medical Information Network database (UMIN000006737).
survival among various drugs coadministered with cisplatin (P ¼ .005). Postoperative chemotherapy significantly improved survival time in stages II and III, and an improvement trend was shown in stage IB, whereas a deteriorating trend was found in stage IA. 5 For patients with metastatic nonsquamous NSCLC, a combination of pemetrexed with cisplatin has been a standard treatment. A randomized phase III study showed the noninferiority in overall survival (OS) of pemetrexed in combination with cisplatin compared with gemcitabine in combination with cisplatin in untreated advanced NSCLC (hazard ratio, 0.94; 95% confidence interval, 0.84-1.05). 6 A subgroup analysis of adenocarcinoma and large-cell carcinoma showed that a combination of pemetrexed with cisplatin showed significantly better survival (adenocarcinoma: 12.6 vs. 10.9 months, P ¼ .03; large-cell carcinoma: 10.4 vs. 6.7 months, P ¼ .03). In a phase III study of pemetrexed compared with docetaxel for previously treated NSCLC, the subgroup analysis of adenocarcinoma also showed that pemetrexed significantly prolonged the survival time. 7 These results suggest that pemetrexed is and pemetrexed (500 mg/m 2 , day 1) every 3 weeks as adjuvant chemotherapy for NSCLC patients. 8 One-hundred thirty-two patients with completely resected stages IB to pT3N1 NSCLC were assigned randomly to vinorelbine with cisplatin or pemetrexed with cisplatin. The primary endpoint was the clinical feasibility (no Grade 4 neutropenia/thrombocytopenia or thrombocytopenia with bleeding, no Grade 3/4 febrile neutropenia or nonhematologic toxicity; no premature withdrawal/death). The feasibility rate was better for the combination of pemetrexed with cisplatin (95.5%) compared with the combination of vinorelbine with cisplatin (75.4%; P ¼ .001). After a 3-year follow-up of the TREAT study, there were no significant differences in the efficacies between these 2 chemotherapy regimens. 9 Second, a randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB/II NSCLC has also been reported. The primary endpoint was treatment feasibility, defined as 4 cycles completed with no cycle delay > 42 days and 2 dose reductions, with a median relative dose intensity 95%; and no Grade 3 toxicities at the follow-up visit 30 days after the final dose. This study involved 122 patients, and neither regimen met the primary endpoint (feasibility rate: 59.4% for pemetrexed with cisplatin and 50% for pemetrexed with carboplatin). 10 These results suggested that a combination of pemetrexed with cisplatin was also feasible as postoperative adjuvant chemotherapy.
On the basis of this background, we conducted a randomized phase III study comparing cisplatin (75 mg/m 
Patients and Methods

Study Design and Objectives
The Japan Intergroup Trial of Pemetrexed Adjuvant Chemotherapy for Completely Resected Nonsquamous NoneSmall-Cell Lung Cancer (JIPANG) study was designed as an open-label, randomized phase III trial to evaluate the efficacy of pemetrexed with cisplatin in patients with completely resected nonsquamous NSCLC compared with vinorelbine with cisplatin as postoperative adjuvant chemotherapy. Patients are randomized in a 1:1 ratio to the experimental arm (pemetrexed with cisplatin) or control arm (vinorelbine with cisplatin), stratified according to sex (female vs. male), age (< 70 years vs. 70 years), pathologic stage (II vs. IIIA), mutation of the epidermal growth factor receptor (EGFR; mutant vs. wild) and institution ( Figure 1 ). The primary endpoint is OS. The secondary endpoints are disease-free survival, rate of treatment completion, and safety. In addition, biomarker analyses for patients enrolled in this study are ongoing.
This study has been conducted in compliance with the principles of the Declaration of Helsinki, and is registered in the University Hospital Medical Information Network database (UMIN000006737).
Key Eligibility Criteria
Key eligibility criteria are patients aged 20 to 75 years, histologically confirmed pathological stage II or IIIA nonsquamous NSCLC (Union for International Cancer Control Tumor, Node, Metastases classification, seventh edition), proven mutation of the EGFR gene, Eastern Cooperative Oncology Group performance status of 0 or 1, as well as adequate hematologic and organ function. Each patient receives complete resections using lobectomy or pneumonectomy with resection of any involved N1 lymph nodes within 3 to 8 weeks before patient enrollment. All patients must sign informed consent forms approved by the review board of each institution.
Key exclusion criteria are severe postoperative complications, interstitial pneumonia on computed tomography of the chest, currently pregnant women, and other severe complications.
Treatment Plan
Patients enrolled in this study will be randomized to receive pemetrexed (500 mg/m 2 ) and cisplatin (75 mg/m 2 ) by intravenous infusion on the first day, or vinorelbine (25 mg/m 2 ) on the first and eighth days and cisplatin (80 mg/m 2 ) on the first day by intravenous infusion. This treatment, defined as "1 cycle," will be repeated every 3 weeks until 4 cycles have been completed.
Statistical Design
The primary endpoint of this study is OS, defined as the duration from patient enrollment to the date of death or the patient's last visit. The 5-year survival rate of patients treated with vinorelbine with cisplatin as the control arm is estimated to be 50% on the basis of previous reports.
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In this study, the 5-year survival rate is expected to be improved by approximately 8%. To carry out the log rank test under the chosen condition (a ¼ 1-sided 0.05; 1-b ¼ 0.8; 3-year registration period and 5-year follow-up after registration of the last patient), 426 events and 777 patients are required. After allowance for exclusion of some patients from analyses, the sample size is planned at 400 patients per arm (a total of 800 patients). A total of 804 patients with pathological stage II to IIIA completely resected nonsquamous NSCLC were enrolled in this study between March 2012 and August 2016.
Discussion
A study on the basis of a Japanese lung cancer registry showed that stage-specific prognoses improved over 1 decade. 11 In addition, 
Conclusion
Cisplatin-based chemotherapy remains standard treatment for patients who have undergone complete resection of stage II to III NSCLC. The JIPANG study will show the optimal chemotherapy regimen for completely resected nonsquamous NSCLC. 
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